[go: up one dir, main page]

MX2020005481A - Purificacion de saponina. - Google Patents

Purificacion de saponina.

Info

Publication number
MX2020005481A
MX2020005481A MX2020005481A MX2020005481A MX2020005481A MX 2020005481 A MX2020005481 A MX 2020005481A MX 2020005481 A MX2020005481 A MX 2020005481A MX 2020005481 A MX2020005481 A MX 2020005481A MX 2020005481 A MX2020005481 A MX 2020005481A
Authority
MX
Mexico
Prior art keywords
saponin
saponin purification
purification
extracts
absorbance
Prior art date
Application number
MX2020005481A
Other languages
English (en)
Inventor
Ahmad Taimour Baig
Garcia Juan Jose Diaz
Chad Austin Farrenburg
Kent Raymond Myers
Jeri Kay Sandvick
Jeb Yeatts Vandenburg
Felicie Georgette Colette Denet
Lora Lea Lawrence
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2020005481A publication Critical patent/MX2020005481A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Extractos de saponina que contienen al menos 93% de pico principal QS-21 y 0.25-3% de componente 2018 por absorbancia UV a 214 nm, métodos para elaborar dichos extractos, su uso como adyuvantes de vacunas y aspectos relacionados.
MX2020005481A 2017-12-01 2018-11-30 Purificacion de saponina. MX2020005481A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593581P 2017-12-01 2017-12-01
EP17209780 2017-12-21
PCT/EP2018/083234 WO2019106192A1 (en) 2017-12-01 2018-11-30 Saponin purification

Publications (1)

Publication Number Publication Date
MX2020005481A true MX2020005481A (es) 2020-12-07

Family

ID=64661325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005481A MX2020005481A (es) 2017-12-01 2018-11-30 Purificacion de saponina.

Country Status (9)

Country Link
US (2) US11591364B2 (es)
EP (1) EP3717001A1 (es)
JP (2) JP2021504424A (es)
CN (1) CN111670044A (es)
BR (1) BR112020010790A2 (es)
CA (1) CA3083078A1 (es)
CL (1) CL2020001440A1 (es)
MX (1) MX2020005481A (es)
WO (1) WO2019106192A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3083059A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin extraction
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
WO2020245207A1 (en) * 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
CA3181627A1 (en) 2020-05-05 2021-11-11 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
CA3188708A1 (en) 2020-08-07 2022-02-10 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
JP2023547197A (ja) 2020-10-28 2023-11-09 サノフィ・パスツール Ｔｌｒ４アゴニストを含有するリポソーム、その製造および使用
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
JP2024538802A (ja) 2021-10-19 2024-10-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンの生成
US20250325655A1 (en) * 2021-12-28 2025-10-23 Chengdu Maxvax Biotechnology LLC Vaccine adjuvant, and preparation method therefor and use thereof
CN114703205A (zh) * 2022-03-11 2022-07-05 上海博唯生物科技有限公司 一种疱疹病毒糖蛋白gE重组蛋白、疫苗、制备方法和应用
WO2024145204A1 (en) * 2022-12-29 2024-07-04 Q-Vant Biosciences, Inc. Modified qs-21 compositions and processes for producing the same and uses therefor
WO2024261351A2 (en) 2024-05-08 2024-12-26 Vaccine Formulation Institute Ch Ltd. Immunologically active saponin fractions and adjuvant formulations

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JP2733263B2 (ja) 1988-10-04 1998-03-30 キヤノン株式会社 集積型光ノードおよびそれを用いたバス型光情報システム
ES2071770T3 (es) 1989-06-27 1995-07-01 Smithkline Beecham Biolog Nuevos compuestos.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
SG48390A1 (en) 1991-11-16 1998-04-17 Smithkline Beecham Biolog Hybrid protein between cs from plasmodium and hbs ag
US6169171B1 (en) 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
US5928902A (en) 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
DK0699076T3 (da) 1993-05-18 2003-03-03 Univ Ohio State Res Found Vaccine mod mellemørebetændelse
KR0184779B1 (ko) 1995-04-13 1999-04-01 성재갑 퀼라야 사포나리아 몰리나로부터 분리정제된 사포닌 변이체, 이의 분리정제 방법 및 이를 함유하는 백신 제형
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
FR2748748B1 (fr) 1996-05-17 1998-11-06 Pasteur Institut Identification et clonage d'un antigene mycobacterien correspondant a une hemagglutine de liaison a l'heparine
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
ES2297841T3 (es) 1996-12-02 2008-05-01 Antigenics Inc. Nuevas composiciones de saponina y usos de las mismas.
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
EP1000144B1 (en) 1997-06-03 2007-12-12 Sanofi Pasteur Limited Lactoferrin receptor gene of moraxella
US6355249B2 (en) 1998-04-17 2002-03-12 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Canada Process for recovery and purification of saponins and sapogenins from quinoa (Chenopodium quinoa)
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
FR2832410B1 (fr) 2001-11-19 2004-04-02 Pasteur Institut Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene
WO2005063802A2 (en) 2003-12-23 2005-07-14 Children's Hospital, Inc. Haemophilus influenzae type iv pili
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ZA200805602B (en) 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2998316B1 (en) 2007-03-02 2019-06-12 GlaxoSmithKline Biologicals S.A. Novel method and compositions
MX2010007107A (es) 2007-12-24 2010-12-21 Id Biomedical Corp Quebec Antigenos de virus del sincicio respiratorio recombinantes.
JP5824360B2 (ja) 2008-07-25 2015-11-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物および方法
DK2315834T3 (en) 2008-07-25 2018-08-20 Glaxosmithkline Biologicals Sa Tuberculosis Rv2386c protein, compositions and uses thereof
HUE031044T2 (en) 2008-07-25 2017-06-28 Glaxosmithkline Biologicals Sa Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
WO2010149657A1 (en) 2009-06-22 2010-12-29 Px Therapeutics Method for the purification of hbha
CA2766211A1 (en) 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
WO2011092253A1 (en) 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
CN103249431B (zh) 2010-12-14 2016-11-02 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
PL2707385T3 (pl) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Prefuzyjne antygeny RSV F
GB201213364D0 (en) 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
MX385818B (es) 2013-03-13 2025-03-18 Us Health Proteínas f de rsv de prefusión y su uso.
GB201316463D0 (en) 2013-09-16 2013-10-30 Giles Clark & Cook Ltd Novel compositions
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
EP3662440B1 (en) 2017-08-04 2021-12-29 Ventana Medical Systems, Inc. Color unmixing with scatter correction
JP6928713B2 (ja) 2017-09-08 2021-09-01 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ 側面遮断ピストンバルブアセンブリ
CA3083059A1 (en) * 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin extraction
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.

Also Published As

Publication number Publication date
WO2019106192A1 (en) 2019-06-06
CL2020001440A1 (es) 2021-02-19
US11591364B2 (en) 2023-02-28
BR112020010790A2 (pt) 2020-11-10
US20200317719A1 (en) 2020-10-08
JP2024001012A (ja) 2024-01-09
JP2021504424A (ja) 2021-02-15
US20230272000A1 (en) 2023-08-31
CA3083078A1 (en) 2019-06-06
EP3717001A1 (en) 2020-10-07
US12227540B2 (en) 2025-02-18
CN111670044A (zh) 2020-09-15

Similar Documents

Publication Publication Date Title
MX2020005481A (es) Purificacion de saponina.
CL2023000198A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
AU366476S (en) Bottle
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
SG10201803042PA (en) Anti-tim-3 antibodies
AU2016261707A8 (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MY191539A (en) Streptococcal vaccine
SA519401227B1 (ar) لقاح النيسرية السحائية
ZA201701000B (en) Attenuated bovine coronavirus and related vaccines
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
EA201692154A1 (ru) Перорально распадающаяся пленка
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX365411B (es) Métodos para reducir el mal olor y las bacterias.
MX2017007577A (es) Compuestos de dihidropirimidin-2-ona y su uso medico.
NZ747261A (en) Stevia-containing beverage
MX2016009445A (es) Composicion de aminas con olor enmascarado.
MX2019013250A (es) 2,3,7-trimetiloct-6-enil acetato y 3,7-dimetil-2-metilen-oct-6-eni l acetato y derivados de estos y su uso como sustancias quimicas aromaticas.
MX391147B (es) Composiciones para diferenciación y proliferación celular que comprenden la combinación de un extracto de acmella oleracea (espilantol) con extracto de camellia sinensis.
EP4505880A3 (en) Stevia extracts
BR112017019154A2 (pt) uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica
MX395174B (es) Composiciones de triptamina y metodos de uso.
GB2560853A (en) Phytochemical recovery from plants
MX2017008655A (es) Derivados de jasmonato y composiciones de los mismos.